D-penicillamine, a chelating agent of copper, is the drug of choice for the treatment of Wilson’s disease. Breast enlargement is a rare complication arising from its use, and we report a case of breast gigantism which developed after it had been used for ten months to treat this condition. Mammography demonstrated bilaterally enlarged dense breasts; ultrasonography, similarly, demonstrated enlargement, revealing the presence of a mass, shown at biopsy to be benign, in the left one.

**Index words:** Breast gigantism
- D-penicillamine, breast enlargement
- Breast

**Case Report**

During a two-month period, a 22-year-old woman noticed gradual enlargement of both breasts. After Wilson’s disease was diagnosed in 1992, D-penicillamine treatment was initiated, but after seven years the medication was withdrawn due to hirsutism. Due to dysarthria and gait disturbance, D-penicillamine treatment (750 mg per day) was restarted, but 10 months later, both breasts had become significantly larger, without mass. Physical examination showed that the breasts were tense, hard, and lumpy [Fig. 1A], and laboratory tests indicated that prolactin levels had risen to 37.9 ng/ml. Levels of both luteinizing and follicle-stimulating hormone were within the normal range, however. Mammography demonstrated bilaterally enlarged dense breasts [Fig. 1B, C]; ultrasonography also demonstrated breast enlargement, together with a benign mass in the left one. Ultrasonography-guided core needle biopsy was performed [Fig. 1D], revealing mild hyperplasia of the myxoid stroma. Three months after discontinuing D-penicillamine, the breasts had reverted to their normal size.

**Discussion**

Wilson’s disease is a congenital disorder of metal metabolism, arising due to a lack of ceruloplasmin. D-penicillamine, as a chelating agent of copper, is the drug of choice for the treatment of the condition (2), and is also an effective treatment for rheumatoid arthritis and systemic sclerosis. D-penicillamine has numerous adverse effects on bone marrow suppression, obligating bron-
Chiolitis, nephritic syndrome, thyroiditis, and polyneuropathy of both the mouth and skin (3, 4). Breast enlargement is an unusual complication, encountered in both pre- and postmenopausal patients with normal or increased prolactin levels (1). The nature of the relationship between D-penicillamine, serum prolactin levels, and breast enlargement has not yet been clearly explained, through a report has indicated that D-penicillamine may alter the circulating prolactin level or the response of the mammary glands to prolactin (5). Only two cases of Breast enlargement and hyperprolactinemia after treatment with D-penicillamine have been reported (6).

Breast tissues are of two major histologic types: parenchymal tissue, which is dependent upon estrogen and progesterone for growth and development, and stromal or connective tissue which, in contrast, is regulated by the pituitary gonadotrophins, prolactin, and growth hormone. Histologic examinations has thus mainly revealed rich connective tissues and no changes in glandular tissues (5, 7), while radiography has demonstrated the presence of large nodules with or without distorted internal architecture and external contours (7).

The interval between the start of treatment and the onset of mammary enlargement has ranged from 12 weeks to 18 months (8). In our case, the enlargement of
both breasts was apparent after ten months. Reports have stated that when D-penicillamine was replaced by danazol, the symptoms subsided, through surgery was sometimes necessary (1, 7).

Breast gigantism is a rare complication of D-penicillamine therapy, and we have described a case in which the condition arose after the drug was used to treat Wilson’s disease. The radiologic findings were bilaterally enlarged breasts with extremely dense fibro-glandular tissue at mammography, and a benign mass at ultrasonography.

References

7. Desaultes JE. Breast gigantism due to D-penicillamine. Can Assoc Radiol J 1994;45:143-144